CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 26 enrolled
Drug / intervention
Grazoprevir +1 moredrug
Likely dose
Grazoprevir 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01716156
NCT01716156Phase 2Completed
CompareCT.gov

A Phase II Randomized Clinical Trial to Study the Efficacy and Safety of MK-5172 in Combination With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Virus Infection

Merck Sharp & Dohme LLC·interventional·Posted Oct 29, 2012·Updated Sep 24, 2018

In Brief

A Phase 2 clinical trial evaluating Grazoprevir and Ribavirin for Hepatitis C. Completed, enrolled 26 participants.

Detailed Summary

This study will compare two different durations of treatment with grazoprevir (MK-5172) in combination with ribavirin (RBV) in treatment-naïve non-cirrhotic interferon-eligible interleukin 28b CC (IL28B CC) genotype participants with genotype 1 (GT1)-positive chronic hepatitis C (CHC). Participants will be randomized to receive 12 or 24 weeks of combination therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedOct 29, 2012
Enrollment StartJan 18, 2013
Primary CompletionDec 9, 2013
Study CompletionMar 12, 2014
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 13.7 years ago

Interventions

Grazoprevirdrug

Grazoprevir, tablet, orally, 100 mg, once per day for 12 or 24 weeks, depending on Arm assignment

Ribavirindrug

Ribavirin capsules, orally, twice per day, at a total daily dose from 800 to 1400 mg based on participant weight